Effect of nitric oxide synthase on multiple drug resistance is related to Wnt signaling in non-small cell lung cancer

Oncology Reports

Volumn 32, Issue 4, 2014, Pages 1703-1708

  Li, Yang ^a   Ma, Chengyuan ^a   Shi, Xu ^b   Wen, Zhongmei ^a   Li, Dan ^a   Sun, Munan ^c   Ding, Hui ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b JILIN UNIVERSITY   (China)

^c Jilin Province People's Hospital   (China)

Author keywords

Drug resistance; Nitric oxide synthase; Non small cell lung cancer; Signaling transduction; Wnt

Indexed keywords

BETA CATENIN; CISPLATIN; DICKKOPF 1 PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); GLUTATHIONE TRANSFERASE; MULTIDRUG RESISTANCE PROTEIN; NITRIC OXIDE SYNTHASE; PROTEIN INHIBITOR; SECRETED FRIZZLED RELATED PROTEIN 1; WNT PROTEIN; DKK1 PROTEIN, HUMAN; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; MEMBRANE PROTEIN; MESSENGER RNA; NOS2 PROTEIN, HUMAN; SFRP1 PROTEIN, HUMAN; SIGNAL PEPTIDE; TUMOR ANTIGEN;

ARTICLE; CANCER CELL; CANCER RESISTANCE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; DRUG RESISTANCE; GENETICS; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; TUMOR CELL LINE; WNT SIGNALING PATHWAY;

ANTIGENS, NEOPLASM; BETA CATENIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GLUTATHIONE TRANSFERASE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MEMBRANE PROTEINS; NITRIC OXIDE SYNTHASE TYPE II; RNA, MESSENGER; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84923068587     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3351     Document Type: Article

References (43)

1. Keith RL and Miller YE: Lung cancer chemoprevention: current status and future prospects. Nat Rev Clin Oncol 10: 334-343, 2013.
2. She J, Yang P, Hong Q and Bai C: Lung cancer in China: challenges and interventions. Chest 143: 1117-1126, 2013.
3. Yang Y, Li H, Hou S, Hu B, Liu J and Wang J: The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell. PLoS One 8: e65309, 2013.
4. Grutters JPC, Kessels AGH, Pijls-Johannesma M, de Ruysscher D, Joore MA and Lambin P: Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. Radiother Oncol 95: 32-40, 2010.
5. Herbst R, Heymach J and Lippman S: Molecular origins of cancer. N Engl J Med 359: 1367-1380, 2008.
6. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98, 2002. (Pubitemid 34438899)
7. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26: 3543-3551, 2008.
8. Mackay HJ, Twelves CJ: Protein kinase C: a target for anticancer drugs? Endocr Relat Cancer 10: 389-396, 2003. (Pubitemid 37267557)
9. Hiss D: Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways. J Oncol 2012: 737981, 2012.
10. Jenkins DC, Charles IG, Thomsen LL, et al: Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA 92: 4392-4396, 1995.
11. Xu WM, Liu LZ, Loizidou M, Ahmed M and Charles IG: The role of nitric oxide in cancer. Cell Res 12: 311-320, 2002. (Pubitemid 135708343)
12. Chen GG, Lee TW, Xu H, Yip JH, Li M, Mok TS and Yim AP: Increased inducible nitric oxide synthase in lung carcinoma of smokers. Cancer 112: 372-381, 2008.
13. Wongvaranon P, Pongrakhananon V, Chunhacha P and Chanvorachote P: Acquired resistance to chemotherapy in lung cancer cells mediated by prolonged nitric oxide exposure. Anticancer Res 33: 5433-5444, 2013.
14. Du Q, Zhang X, Liu Q, Zhang X, Bartels CE and Geller DA: Nitric oxide production upregulates Wnt/β-catenin signaling by inhibiting Dickkopf-1. Cancer Res 73: 6526-6537, 2013.
15. Vane JR, Mitchell JA, Appleton I, et al: Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci USA 91: 2046-2050, 1994. (Pubitemid 24092039)
16. Nathan C and Xie QW: Nitric oxide synthases: roles, tolls, and controls. Cell 78: 915-918, 1994. (Pubitemid 24292319)
17. Gonzalez D, Rojas A, Herrera MB and Conlan RS: iNOS activation regulates β-catenin association with its partners in endothelial cells. PLoS One 7: e52964, 2012.
18. Sumi T, Oki S, Kitajima K and Meno C: Epiblast ground state is controlled by canonical Wnt/β-catenin signaling in the postimplantation mouse embryo and epiblast stem cells. PLoS One 8: e63378, 2013.
19. Tian XH, Hou WJ, Fang Y, et al : XAV939, a tankyrase 1 inhibitor, promotes cell apoptosis in neuroblastoma cell lines by inhibitingWnt/β- catenin signaling pathway. J Exp Clin Cancer Res 32: 100, 2013.
20. Gafni J, Munsch JA, Lam TH, et al: Xestospongins: potent membrane permeable blockers of the inositol 1,4,5-trisphosphate receptor. Neuron 19: 723-733, 1997. (Pubitemid 27430757)
21. Westfall TA, Brimeyer R, Twedt J, et al: Wnt-5/pipetail functions in vertebrate axis formation as a negative regulator of Wnt/beta?catenin activity. J Cell Biol 162: 889-898, 2003. (Pubitemid 37087728)
22. Cadigan KM and Nusse R: Wnt signaling: a common theme in animal development. Genes Dev 11: 3286-3305, 1997. (Pubitemid 28023954)
23. Logan CY and Nusse R: The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20: 781-810, 2004. (Pubitemid 39488658)
24. Moon RT, Brown JD and Torres M: WNTs modulate cell fate and behavior during vertebrate development. Trends Genet 13: 157-162, 1997. (Pubitemid 27191521)
25. Nakajima M, Fukuchi M, Miyazaki T, Masuda N, Kato H and Kuwano H: Reduced expression of Axin correlates with tumour progression of oesophageal squamous cell carcinoma. Br J Cancer 88: 1734-1739, 2003. (Pubitemid 36760418)
26. Bryja V, Andersson ER, Schambony A, et al: The extracellular domain of Lrp5/6 inhibits noncanonical Wnt signaling in vivo. Mol Biol Cell 20: 924-936, 2009.
27. Andersson ER, Bryjova L, Biris K, Yamaguchi TP, Arenas E and Bryja V: Genetic interaction between Lrp6 and Wnt5a during mouse development. Dev Dyn 239: 237-245, 2010.
28. Gao C, Chen YG: Dishevelled: The hub of Wnt signaling. Cell Signal 22: 717-727, 2010.
29. Mikels AJ and Nusse R: Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol 4: 570-582, 2006.
30. Surana R, Sikka S, Cai W, Dharmarajan AM, Kumar AP et al: Secreted frizzled related proteins: implications in cancers. Biochim Biophys Acta 1845: 53-65, 2014.
31. Zhang J, Zhou B, Liu Y, et al : Wnt inhibitory factor-1 functions as a tumor suppressor through modulating Wnt/β-catenin signaling in neuroblastoma. Cancer Lett 348: 12-19, 2014.
32. Kawano Y and Kypta R: Secreted antagonists of the Wnt signalling pathway. J Cell Sci 116: 2627-2634, 2003. (Pubitemid 36857216)
33. Bafico A, Liu G, Yaniv A, Gazit A and Aaronson SA: Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat Cell Biol 3: 683-686, 2001. (Pubitemid 32624426)
34. Du Q, Park KS, Guo Z, et al: Regulation of human nitric oxide synthase 2 expression by Wnt beta-catenin signaling. Cancer Res 66: 7024-7031, 2006. (Pubitemid 44197678)
35. Du Q, Zhang X, Cardinal J, et al: Wnt/beta-catenin signaling regulates cytokine-induced human inducible nitric oxide synthase expression by inhibiting nuclear factor-kappaB activation in cancer cells. Cancer Res 69: 3764-3771, 2009.
36. Du Q and Geller DA: Cross-regulation between Wnt and NF-κB signaling pathways. For Immunopathol Dis Therap 1: 155-181, 2010.
37. Pakos EE and Ioannidis JP: The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis. Cancer 8: 581-589, 2003. (Pubitemid 36885999)
38. Geng G, Wang L, Chen X, Cao R and Li P: The association between chemosensitivity and Pgp, GST-π and Topo II expression in gastric cancer. Diagn Pathol 8: 198, 2013.
39. MacDonald BT and He X: Frizzled and LRP5/6 receptors for Wnt/β-catenin signaling. Cold Spring Harb Perspect Biol 4: a007880, 2012.
40. Bourhis E, Tam C, Franke Y, et al : Reconstitution of a Frizzled8?Wnt3a-LRP6 signaling complex reveals multiple Wnt and Dkk1 binding sites on LRP6. J Biol Chem 285: 9172-9179, 2010.
41. Tamai K, Semenov M, Kato Y, et al : LDL-receptor-related proteins in Wnt signal transduction. Nature 407: 530-535, 2000.
42. Hsieh JC, Kodjabachian L, Rebbert ML, et al: A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature 398: 431-436, 1999. (Pubitemid 29180376)
43. Surmann-Schmitt C, Widmann N, Dietz U, et al: Wif-1 is expressed at cartilage-mesenchyme interfaces and impedes Wnt3a-mediated inhibition of chondrogenesis. J Cell Sci 122: 3627-3637, 2009.